Evolutionary trajectory of bacterial resistance to antibiotics and antimicrobial peptides in Escherichia coli

ABSTRACT The global crisis of antimicrobial resistance poses a major threat to human health, underscoring the urgency of developing new antibacterial strategies. Antimicrobial peptides (AMPs) are promising alternatives to antibiotic therapy, yet potential microbial resistance is of great concern. Re...

Full description

Saved in:
Bibliographic Details
Main Authors: Feiyu Yu, Dejuan Wang, Haijie Zhang, Zhiqiang Wang, Yuan Liu
Format: Article
Language:English
Published: American Society for Microbiology 2025-03-01
Series:mSystems
Subjects:
Online Access:https://journals.asm.org/doi/10.1128/msystems.01700-24
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850038996528267264
author Feiyu Yu
Dejuan Wang
Haijie Zhang
Zhiqiang Wang
Yuan Liu
author_facet Feiyu Yu
Dejuan Wang
Haijie Zhang
Zhiqiang Wang
Yuan Liu
author_sort Feiyu Yu
collection DOAJ
description ABSTRACT The global crisis of antimicrobial resistance poses a major threat to human health, underscoring the urgency of developing new antibacterial strategies. Antimicrobial peptides (AMPs) are promising alternatives to antibiotic therapy, yet potential microbial resistance is of great concern. Resistance is often accompanied by fitness costs, which may in turn influence the spread of drug-resistant bacteria and their susceptibility to other antimicrobial agents. Herein, we investigate the evolutionary trajectory of bacterial resistance to antibiotics and AMPs in Escherichia coli, and evaluate the fitness costs and collateral sensitivity of drug-resistant strains. We reveal that E. coli develops resistance to antibiotics, particularly ciprofloxacin and kanamycin, at a notably faster rate than to AMPs. Moreover, antibiotic-evolved strains exhibit slightly higher fitness costs than AMP-evolved bacteria, primarily manifested in reduced bacterial growth and swimming motility. Notably, we demonstrate that trimethoprim-resistant E. coli, with mutations in thyA gene, displays enhanced susceptibility to pexiganan, as evidenced by both in vitro and in vivo studies. Overall, our findings shed new insights for the clinical deployment of AMPs and propose innovative therapeutic strategies for combating antibiotic-resistant bacterial infections.IMPORTANCEThe global spread of antimicrobial resistance necessitates the development of innovative anti-infective strategies. Antimicrobial peptides (AMPs) represent promising alternatives in the post-antibiotic era. By monitoring the evolutionary trajectory of bacterial resistance to eight antibiotics and ten AMPs in Escherichia coli, we demonstrate that E. coli exhibits slower emergence of resistance against AMPs compared with antibiotics. Additionally, these antibiotic-resistant strains incur significant fitness costs, particularly in bacterial growth and motility. Most importantly, we find that some antibiotic-resistant strains show collateral sensitivity to specific AMPs in both in vitro and animal infection models, which is conducive to accelerating the development of AMP-based antibacterial treatment.
format Article
id doaj-art-ce9ac3219e504cd0a28efd76e3726d2a
institution DOAJ
issn 2379-5077
language English
publishDate 2025-03-01
publisher American Society for Microbiology
record_format Article
series mSystems
spelling doaj-art-ce9ac3219e504cd0a28efd76e3726d2a2025-08-20T02:56:27ZengAmerican Society for MicrobiologymSystems2379-50772025-03-0110310.1128/msystems.01700-24Evolutionary trajectory of bacterial resistance to antibiotics and antimicrobial peptides in Escherichia coliFeiyu Yu0Dejuan Wang1Haijie Zhang2Zhiqiang Wang3Yuan Liu4Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, College of Veterinary Medicine, Yangzhou University, Yangzhou, ChinaJiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, College of Veterinary Medicine, Yangzhou University, Yangzhou, ChinaJiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, College of Veterinary Medicine, Yangzhou University, Yangzhou, ChinaJiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, College of Veterinary Medicine, Yangzhou University, Yangzhou, ChinaJiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, College of Veterinary Medicine, Yangzhou University, Yangzhou, ChinaABSTRACT The global crisis of antimicrobial resistance poses a major threat to human health, underscoring the urgency of developing new antibacterial strategies. Antimicrobial peptides (AMPs) are promising alternatives to antibiotic therapy, yet potential microbial resistance is of great concern. Resistance is often accompanied by fitness costs, which may in turn influence the spread of drug-resistant bacteria and their susceptibility to other antimicrobial agents. Herein, we investigate the evolutionary trajectory of bacterial resistance to antibiotics and AMPs in Escherichia coli, and evaluate the fitness costs and collateral sensitivity of drug-resistant strains. We reveal that E. coli develops resistance to antibiotics, particularly ciprofloxacin and kanamycin, at a notably faster rate than to AMPs. Moreover, antibiotic-evolved strains exhibit slightly higher fitness costs than AMP-evolved bacteria, primarily manifested in reduced bacterial growth and swimming motility. Notably, we demonstrate that trimethoprim-resistant E. coli, with mutations in thyA gene, displays enhanced susceptibility to pexiganan, as evidenced by both in vitro and in vivo studies. Overall, our findings shed new insights for the clinical deployment of AMPs and propose innovative therapeutic strategies for combating antibiotic-resistant bacterial infections.IMPORTANCEThe global spread of antimicrobial resistance necessitates the development of innovative anti-infective strategies. Antimicrobial peptides (AMPs) represent promising alternatives in the post-antibiotic era. By monitoring the evolutionary trajectory of bacterial resistance to eight antibiotics and ten AMPs in Escherichia coli, we demonstrate that E. coli exhibits slower emergence of resistance against AMPs compared with antibiotics. Additionally, these antibiotic-resistant strains incur significant fitness costs, particularly in bacterial growth and motility. Most importantly, we find that some antibiotic-resistant strains show collateral sensitivity to specific AMPs in both in vitro and animal infection models, which is conducive to accelerating the development of AMP-based antibacterial treatment.https://journals.asm.org/doi/10.1128/msystems.01700-24antibioticsantimicrobial resistanceantimicrobial peptidefitness costcollateral sensitivity
spellingShingle Feiyu Yu
Dejuan Wang
Haijie Zhang
Zhiqiang Wang
Yuan Liu
Evolutionary trajectory of bacterial resistance to antibiotics and antimicrobial peptides in Escherichia coli
mSystems
antibiotics
antimicrobial resistance
antimicrobial peptide
fitness cost
collateral sensitivity
title Evolutionary trajectory of bacterial resistance to antibiotics and antimicrobial peptides in Escherichia coli
title_full Evolutionary trajectory of bacterial resistance to antibiotics and antimicrobial peptides in Escherichia coli
title_fullStr Evolutionary trajectory of bacterial resistance to antibiotics and antimicrobial peptides in Escherichia coli
title_full_unstemmed Evolutionary trajectory of bacterial resistance to antibiotics and antimicrobial peptides in Escherichia coli
title_short Evolutionary trajectory of bacterial resistance to antibiotics and antimicrobial peptides in Escherichia coli
title_sort evolutionary trajectory of bacterial resistance to antibiotics and antimicrobial peptides in escherichia coli
topic antibiotics
antimicrobial resistance
antimicrobial peptide
fitness cost
collateral sensitivity
url https://journals.asm.org/doi/10.1128/msystems.01700-24
work_keys_str_mv AT feiyuyu evolutionarytrajectoryofbacterialresistancetoantibioticsandantimicrobialpeptidesinescherichiacoli
AT dejuanwang evolutionarytrajectoryofbacterialresistancetoantibioticsandantimicrobialpeptidesinescherichiacoli
AT haijiezhang evolutionarytrajectoryofbacterialresistancetoantibioticsandantimicrobialpeptidesinescherichiacoli
AT zhiqiangwang evolutionarytrajectoryofbacterialresistancetoantibioticsandantimicrobialpeptidesinescherichiacoli
AT yuanliu evolutionarytrajectoryofbacterialresistancetoantibioticsandantimicrobialpeptidesinescherichiacoli